Merck, Sharpe, and Dohme (MSD) and Singapore’s Economic Development Board  jointly 

 plans for significant investments by MSD to improve its existing manufacturing  facilities in Singapore, as well as for new manufacturing, marketing, and  research activities. MSD plans to invest more than $250 million over the next  10 years. The investments will go towards site improvements at its existing  facilities in Tuas, expansion of its biotech operations, and addition of  technology capabilities to support new product launches. In addition, MSD will  commit to new expenditures of $700 million for local research activities.

  In a press release, Dr. Beh Swan Gin, managing director of the Economic  Development Board said, “We are encouraged that this will pave the way for  Singapore to continue to enhance our capabilities as an integrated global  pharmaceutical site in Asia, across manufacturing, R&D and commercial  operations.”

MSD has a significant presence in Singapore, with approximately 1500  employees in manufacturing, marketing, sales, and the Translational Medicines  Research Center. The total value of MSD’s investments in the area is estimated  to be $1.5 billion.

News

Merck, Sharpe, and Dohme (MSD) and Singapore?s Economic Development Board jointly announced plans for significant investments by MSD to improve its existing manufacturing facilities in Singapore, as well as for new manufacturing, marketing, and research activities.